{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:20:14Z","timestamp":1794806414905,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/s41416-018-0082-1","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T12:56:05Z","timestamp":1526302565000},"page":"1425-1433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers"],"prefix":"10.1038","volume":"118","author":[{"given":"Jorge","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Godin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"McEachern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick","family":"Vishwanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet Elizabeth","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"82_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","volume":"571","author":"TL Aho","year":"2004","unstructured":"Aho, T. L. et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 571, 43\u201349 (2004).","journal-title":"FEBS Lett."},{"key":"82_CR2","doi-asserted-by":"publisher","first-page":"45358","DOI":"10.1074\/jbc.M307933200","volume":"278","author":"B Yan","year":"2003","unstructured":"Yan, B. et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J. Biol. Chem. 278, 45358\u201345367 (2003).","journal-title":"J. Biol. Chem."},{"key":"82_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0167-4889(02)00347-6","volume":"1593","author":"Z Wang","year":"2002","unstructured":"Wang, Z. et al. Phosphorylation of the cell cycle inhibitor p21Cip1\/WAF1 by Pim-1 kinase. Biochim Biophys. Acta 1593, 45\u201355 (2002).","journal-title":"Biochim Biophys. Acta"},{"key":"82_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4161\/cc.2.3.383","volume":"2","author":"LM Winn","year":"2003","unstructured":"Winn, L. M., Lei, W. & Ness, S. A. Pim-1 phosphorylates the DNA binding domain of c-Myb. Cell Cycle 2, 258\u2013262 (2003).","journal-title":"Cell Cycle"},{"key":"82_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0092-8674(84)90309-X","volume":"37","author":"HT Cuypers","year":"1984","unstructured":"Cuypers, H. T. et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37, 141\u2013150 (1984).","journal-title":"Cell"},{"key":"82_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/0092-8674(89)90589-8","volume":"56","author":"M Lohuizen van","year":"1989","unstructured":"van Lohuizen, M. et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56, 673\u2013682 (1989).","journal-title":"Cell"},{"key":"82_CR7","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.1073\/pnas.86.22.8857","volume":"86","author":"R Amson","year":"1989","unstructured":"Amson, R. et al. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl Acad. Sci. USA 86, 8857\u20138861 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"82_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/leu.2011.60","volume":"25","author":"J Asano","year":"2011","unstructured":"Asano, J. et al. The serine\/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 25, 1182\u20131188 (2011).","journal-title":"Leukemia"},{"key":"82_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/10428190310001641251","volume":"45","author":"AM Cohen","year":"2004","unstructured":"Cohen, A. M. et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk. Lymphoma 45, 951\u2013955 (2004).","journal-title":"Leuk. Lymphoma"},{"key":"82_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1600-0609.2005.00429.x","volume":"74","author":"CB Poulsen","year":"2005","unstructured":"Poulsen, C. B. et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur. J. Haematol. 74, 453\u2013465 (2005).","journal-title":"Eur. J. Haematol."},{"key":"82_CR11","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1016\/j.bmcl.2012.05.098","volume":"22","author":"LA Dakin","year":"2012","unstructured":"Dakin, L. A. et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg. Med Chem. Lett. 22, 4599\u20134604 (2012).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"82_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","volume":"123","author":"EK Keeton","year":"2014","unstructured":"Keeton, E. K. et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123, 905\u2013913 (2014).","journal-title":"Blood"},{"key":"82_CR13","first-page":"dju407","volume":"107","author":"AN Kirschner","year":"2014","unstructured":"Kirschner, A. N. et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J. Natl. Cancer Inst. 107, dju407 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"82_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","volume":"26","author":"JM Skolnik","year":"2008","unstructured":"Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D. & Adamson, P. C. Shortening the timeline of pediatric phase I trials: the rolling six design. J. Clin. Oncol. 26, 190\u2013195 (2008).","journal-title":"J. Clin. Oncol."},{"key":"82_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood-2014-04-565754","volume":"124","author":"LS Chen","year":"2014","unstructured":"Chen, L. S., Keating, M. J. & Gandhi, V. Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. Blood 124, 1192\u20131195 (2014).","journal-title":"Blood"},{"key":"82_CR16","unstructured":"The University of Texas MD Anderson Cancer Center. Functional Proteomics RPPA Core Facility. www.mdanderson.org\/research\/research-resources\/core-facilities\/functional-proteomics-rppa-core.html (2017)."},{"key":"82_CR17","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson, B. D. et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 21, 4642\u20134649 (2003).","journal-title":"J. Clin. Oncol."},{"key":"82_CR18","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","volume":"102","author":"H Kantarjian","year":"2003","unstructured":"Kantarjian, H. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379\u20132386 (2003).","journal-title":"Blood"},{"key":"82_CR19","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.3109\/10428194.2016.1166489","volume":"57","author":"LS Chen","year":"2016","unstructured":"Chen, L. S., Yang, J. Y., Liang, H., Cortes, J. E. & Gandhi, V. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk. Lymphoma 57, 2863\u20132873 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"82_CR20","doi-asserted-by":"crossref","unstructured":"Raab MS, et al. Phase 1 study update of the novel Pan\u2013Pim kinase inhibitor LGH447 in patients with relapsed\/refractory multiple myeloma. Blood. 124, abstr. 301 (2014).","DOI":"10.1182\/blood.V124.21.301.301"},{"key":"82_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc2986","volume":"11","author":"MC Nawijn","year":"2011","unstructured":"Nawijn, M. C., Alendar, A. & Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 11, 23\u201334 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"82_CR22","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.ejca.2008.06.044","volume":"44","author":"N Shah","year":"2008","unstructured":"Shah, N. et al. Potential roles for the PIM1 kinase in human cancer\u2014a molecular and therapeutic appraisal. Eur. J. Cancer 44, 2144\u20132151 (2008).","journal-title":"Eur. J. Cancer"},{"key":"82_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.phrs.2013.01.005","volume":"70","author":"W Kim","year":"2013","unstructured":"Kim, W. et al. PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells. Pharmacol. Res 70, 90\u2013101 (2013).","journal-title":"Pharmacol. Res"},{"key":"82_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4161\/cbt.24343","volume":"14","author":"D Xu","year":"2013","unstructured":"Xu, D. et al. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol. Ther. 14, 492\u2013501 (2013).","journal-title":"Cancer Biol. Ther."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0082-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:16Z","timestamp":1684616536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0082-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["82"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0082-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. has received research support from, and served as a consultant for, AstraZeneca. D.J.D. has received honoraria from AstraZeneca for participation in advisory boards. Jde.B. has served on AstraZeneca advisory boards. L.S.C. has received honoraria from AstraZeneca for participation in advisory boards. V.G. has received research support and honoraria from AstraZeneca for participation in advisory boards. R.G., K.V. and J.E.P. are employees of, and hold stock in, AstraZeneca. K.K. and K.M. are former employees of AstraZeneca. E.D. is currently employed by AstraZeneca but for the duration of the study was affiliated to The Christie NHS Foundation Trust and The University of Manchester. E.D.\u2019s former institution\u2014The Christie NHS Foundation Trust\u2014has received commercial income from AstraZeneca. The clinical research was supported by Experimental Cancer Medicine grant award C1467\/A15578. K.T., D.L., M.M., G.L.U. and H.K. have no conflicts of interest or disclosures to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Prior to participation in either study, all patients signed an informed consent document approved by the Institutional Review Board. For the solid tumour study, ethical approval was given by the Institutional Review Boards at the three study sites: National Cancer Center Hospital (Tokyo, Japan), the Christie Hospital NHS Trust (Manchester, UK) and the Institute of Cancer Research and Royal Marsden NHS Foundation (Surrey, UK). For the AML study, ethical approval was given by the Institutional Review Boards at the four study sites: MD Anderson Cancer Center (Houston, USA), Dana-Farber Cancer Institute (Boston, USA), Princess Margaret Hospital (Toronto, Canada), and Washington University School of Medicine (St Louis, USA). Both studies were conducted according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}